Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.32 +0.04 (+0.08%)
Streaming Delayed Price Updated: 12:56 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,... 
Via FinancialNewsMedia
Exposures COVID-19
Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. 
Via Benzinga
Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have  
Via Benzinga
5 Things To Expect This Week
While the "January effect" was rather disappointing, February kicks off with an important week ahead for many types of investors. 
Via InvestorPlace
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a posi 
Via Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at... 
Via FinancialNewsMedia
Why Jim Cramer Like NextEra Energy And Lincoln Electric?
On CNBC’s "Mad Money Lightning Round," Jim Cramer said NextEra Energy, Inc. (NYSE: 
Via Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in... 
Via Benzinga
Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares
Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year Connect Biopharma... 
Via Benzinga
Acasti Pharma: Bouncing Back With a New Drug Pipeline
Picture credit: Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,... 
Via FinancialNewsMedia
Exposures COVID-19
Sanofi Expects Q4 FY21 Vaccine Sales Lower Than Year-Ago, Positive Currency Impact
Sanofi SA (NASDAQ: SNY) says the preliminary estimate of currency impact on Q4 sales and business EPS is approximately +1.5% and +2.5%. Also, the Company expects... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
3 Cathie Wood Stocks To Buy On The Dip
Institutional investor Cathie Wood gained popularity after her ETFs generated big gains last year. Wood asserted recently that her stocks are poised for long-term gains. Hence, we think investing in... 
Via Talk Markets
Plague Year Reversal
Just in time for Christmas, the market decided to go up today pretty much across the board. 
Via Talk Markets
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
Sanofi Agrees To Buy US-Based Amunix Pharma For $1B Upfront
Sanofi SA (NASDAQ: SNY) will buy an immuno-oncology company, Amunix Pharmaceuticals Inc, for an upfront payment of about $1 billion. Sanofi will also pay Amunix up... 
Via Benzinga
GlaxoSmithKline: Investing In Vaccines
GlaxoSmithKline, based in London, is a global healthcare company engaged in the discovery, development, manufacture, and marketing of pharmaceutical and consumer healthcare products. Let's take a look... 
Via Talk Markets
Raising Rates
The Bank of England raised its interest rate to 0.25%, setting a pattern for other countries. 
Via Talk Markets
How Will Moderna Stock Weather Omicron? — And Other Questions Clouding 2022
Analysts call for a sales and earnings decline in 2022. Can Moderna stave it off? 
Via Investor's Business Daily
Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year.... 
Via Benzinga
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron... 
Via Benzinga
3 Stocks That Can Make You Rich in Just a Few Years
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed. 
Via InvestorPlace
Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients
Sanofi SA (NASDAQ: SNY) presented data from two Phase 3 studies of fitusiran for the prophylactic treatment with hemophilia A or B, with or without inhibitors.... 
Via Benzinga
Are Cannabinoids the Next Frontier of Pharmaceuticals? This Company Thinks So and Wants to Lead the Pack
Photo by Michael Longmire on... 
Via Benzinga
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at... 
Via Benzinga
Inflation Surge
Today the market failed to brush off inflation fears as it had done later on Thursday as inflation is at a 4 decade high. 
Via Talk Markets
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.